Related Experiment Video
Updated: Feb 10, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Consensus and Challenges
Furqan Khattak1, Mian B Alam2, Timir K Paul3
1Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Insights
Direct oral anticoagulants (DOACs) offer stroke prevention for nonvalvular atrial fibrillation (AF) but lack antidotes and head-to-head comparisons. This review examines their pros and cons versus warfarin.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases stroke risk.
- Warfarin, a traditional anticoagulant, has limitations due to drug and food interactions.
- Direct oral anticoagulants (DOACs) are emerging as alternatives for stroke prevention in nonvalvular AF.
Purpose of the Study:
- To review the advantages and disadvantages of oral antithrombotics for nonvalvular AF.
- To emphasize the characteristics of DOACs in stroke prevention.
- To highlight the current challenges with DOACs, including lack of antidotes and comparative data.
Main Methods:
- Literature review of approved oral antithrombotics for nonvalvular AF.
- Discussion of DOACs' individual properties, benefits, and drawbacks.
- Comparison of DOACs with warfarin, considering monitoring and interaction profiles.
Main Results:
- DOACs offer convenience by not requiring frequent blood monitoring, unlike warfarin.
- DOACs have not been extensively studied in valvular AF, a high-risk population.
- A significant challenge for DOACs is the absence of readily available antidotes.
- There is a lack of direct head-to-head clinical trials comparing different DOACs.
Conclusions:
- DOACs represent a significant advancement in stroke prevention for nonvalvular AF.
- Further research is needed to address the safety concerns and comparative efficacy of DOACs.
- Clinical decisions regarding anticoagulation in AF require careful consideration of individual patient factors and agent characteristics.
Abstract:
Atrial fibrillation (AF) is associated with high risk of systemic thromboembolism leading to significant morbidity and mortality. Warfarin, previously the mainstay for stroke prevention in AF, requires close monitoring because of multiple food and drug interactions. In recent years, food and drug administration has approved several direct oral anticoagulants (DOACs) for use in patients with nonvalvular AF. These agents have not been studied in patients with valvular AF who are at an even higher risk of systemic thromboembolism. DOACs do not require frequent blood testing or changes in dosage except when renal function deteriorates, however, the lack of established antidotes for many of these agents remains a challenge. Also, currently there is no head-to-head comparison between these agents to guide clinical choice. This article discusses the advantages and disadvantages of currently approved oral antithrombotics in nonvalvular AF, with a special emphasis on the DOACs and their individual characteristics.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils
01:11Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
00:59Gene Therapy
01:26Group Therapy
01:22Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...